Geissler M, Tannapfel A, Reinacher-Schick A, Martens U, et al. Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC). Ann Oncol 2019;30 Suppl 4:iv119-iv120.
PMID: 32084996